Retatrutide
Phase 3Peptide
Eli LillyRetatrutide is a peptide that works as a Gip/glp-1/glucagon Triple Agonist.[2] It is being investigated across 4 indications, with its most advanced program in Phase 3.[1]
Retatrutide is one of 155 peptide programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.
4
Indications
20
Total Trials
12
Active Trials
154
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
177 competitors in Obesity
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Synthroid
IInstitut Jerome Lejeune
Phase 3
Vivia
SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 3
Maridebart Cafraglutide
AmgenPhase 3
HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Retatrutide
Eli LillyPhase 3
Mibavademab
RegeneronPhase 3
PF-08653944
PfizerPhase 3
Aleniglipron
GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity6 trials
Type 2 Diabetes4 trials
Overweight2 trials
Tics1 trial
6 more indications
Type 2 Diabetes Mellitus1 trial
Osteoarthritis1 trial
Atherosclerotic Cardiovascular Disease (ASCVD)1 trial
Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial
Diabetes Mellitus1 trial
Diabetes Mellitus, Type 21 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Retatrutide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]